Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Neoadjuvant letrozole ± BYL719 or buparlisib in HR-positive HER2-negative breast cancer
2013-001862-41Phase 2Completed
- Sponsor
- Novartis
- Start
- Oct 2013
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in breast cancer comparing Letrozole + BYL719, Letrozole + buparlisib and Letrozole + placebo (3 arms). Primary endpoint: Pathologic complete response. Started Oct 2013; status: completed.
02
Drugs
letrozolealpelisibbuparlisib
03
Conditions
breast cancer
Beyond the preview
Go deeper on 2013-001862-41.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2013-001862-41.